FLCCC Alliance Invited to the National Institutes of Health (NIH) COVID-19 Treatment Guidelines Panel to Present Latest Data on Ivermectin FLCCC Urges Expedited Review of Current Data and an Updated NIH Guidance
On January 6, 2021, Drs. Pierre Kory and Paul Marik, founding members of the Front Line COVID-19 Critical Care Alliance (FLCCC), appeared before the National Institutes of Health COVID-19 Treatment Guidelines Panel. The panel, which is in the process of reviewing the rapidly emerging data on the role of ivermectin in the prevention and treatment of COVID-19, invited Drs. Kory and Marik to present the latest data, along with Dr. Andrew Hill—a senior research fellow at the University of Liverpool, who was hired by UNITAID to provide research for the World Health Organization (WHO). The NIH invited the FLCCC members and Dr. Hill to the panel to present the four months of data on ivermectin that has emerged since the NIH last issued its guidelines on August 27. During the meeting, the FLCCC and Dr. Hill pressed the NIH to reevaluate their recommendation for ivermectin. The doctors explained to the panel that numerous clinical studies—including peer-reviewed randomized controlled trials—showed large magnitude benefits of ivermectin in prophylaxis, early treatment and also in late-stage disease. Taken together, the doctors reported that the dozens of clinical trials that have now emerged from around the world are substantial enough to reliably assess clinical efficacy. Specifically, the FLCCC physicians and Dr. Hill presented data from 18 randomized controlled trials that included over 2,100 patients. The trial results demonstrated that ivermectin produces faster viral clearance, faster time to hospital discharge, faster time to clinical recovery, and a 75% reduction in mortality rates.
“In order to save thousands who will die while waiting for their turn to receive the vaccine, it is imperative that treatment guidelines issued by the NIH over four months ago be updated to reflect the strength of the data for ivermectin in prophylaxis, early treatment, and late-stage disease,” said Dr. Kory, FLCCC president, following the hearing.
The NIH panel signaled their intention to consider the data and anticipates an update to their current recommendations by early February.